Menu
Du musst dich anmelden oder registrieren, bevor du fortfahren kannst.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€127.80

€127.80

-0.320%
-0.4
-0.320%
€263.97
 
02.07.25 / Tradegate WKN: 932242 / Symbol: ICLR / Name: ICON / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:
Loading data...
Your prediction

Financial data and news for ICON

sharewise wants to provide you with the best news and tools for ICON, so we directly link to the best financial data sources.

News

ICON plc Schedules Second Quarter 2025 Earnings Conference Call
ICON plc Schedules Second Quarter 2025 Earnings Conference Call


ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that it will release its financial results for the second quarter 2025

ICON plc to Present at the William Blair 45th Annual Growth Stock Conference
ICON plc to Present at the William Blair 45th Annual Growth Stock Conference


ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the William Blair

ICON releases its ICON Cares 2024 Report
ICON releases its ICON Cares 2024 Report


ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today releases its ICON Cares 2024 Report. The report outlines how the company is

Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies


ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from

ICON Reports First Quarter 2025 Results
ICON Reports First Quarter 2025 Results


ICON plc (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today reported its financial results for the first quarter ended March 31, 2025.



CEO

ICON plc Schedules First Quarter 2025 Earnings Conference Call
ICON plc Schedules First Quarter 2025 Earnings Conference Call


ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that it will release its financial results for the first quarter 2025

ICON plc to Present at Upcoming Investor Conferences
ICON plc to Present at Upcoming Investor Conferences


ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Leerink

ICON Reports Fourth Quarter and Full Year 2024 Results
ICON Reports Fourth Quarter and Full Year 2024 Results


ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the fourth quarter and full year ended December 31

ICON Portfolio of AI Tools Drives Clinical Trial Efficiencies
ICON Portfolio of AI Tools Drives Clinical Trial Efficiencies


ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the expansion of its portfolio of artificial intelligence (AI) tools that

ICON plc Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call
ICON plc Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call


ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will release financial results for the fourth quarter and full year 2024

ICON Issues Financial Guidance for Full Year 2025
ICON Issues Financial Guidance for Full Year 2025


ICON plc, (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2025. For the

Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey
Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey


ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals

ICON plc to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ICON plc to Present at the 43rd Annual J.P. Morgan Healthcare Conference


ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 43rd Annual J.P